Dr. Marc Poirot is Research Director at the Institute National de la Santé et de la Recherche Medicale (INSERM). He Heads the team Sterol Metabolism and Therapeutic Innovations in Oncology (Toulouse, France) with Dr. Sandrine Silvente-Poirot at the Cancer Research Center of Toulouse. He received a PhD in Chemical Biology (1991) from the University of Toulouse (France). He did a Post-doctorate at Sanofi in 1991 before becoming tenured at INSERM. He was Visiting Scientist in the laboratory of Dr Stoney S. Simons Jr (NIDDK/NIH, Bethesda, USA) to study Steroid Hormone Receptors. Since then, his research has focused on the identification of off-targets of the anti-tumor drug tamoxifen, which led to the definition of the importance of Cholesterol Metabolism in the Pharmacology of Antiestrogens. He trained 10 of postgraduate students. He has published 68 SCI journal paper. He also served as an evaluation expert for organizations. He is co-founder of the Biotech Company Affichem, which develops small natural molecules for therapeutic applications. He is member of the executive board and chairman of the scientific board of Affichem, Innovative, translational and longstanding research has ever been a pursuit in his academic career. He is associate editor for Frontiers in Nutrition, Frontiers in Pharmacology, Frontiers in Chemistry, Frontiers in Oncology, Nature publishing group. He is also serving as reviewer and editor of number of journals. He is member of Groupe de recherche sur les lipides, Société Française de Chimie Therapeutique, American Association for Cancer Research, American Society of Pharmacology and Experimental Therapeutics, European Network on Oxysterol Research, and Asian Council of Science Editors.